Technical Analysis for LRMR - Larimar Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Fell Below 50 DMA | Bearish | -0.67% | |
| Outside Day | Range Expansion | -0.67% | |
| Wide Bands | Range Expansion | -0.67% | |
| NR7 | Range Contraction | -6.23% | |
| Inside Day | Range Contraction | -6.23% |
| Alert | Time |
|---|---|
| Fell Below 20 DMA | 1 day ago |
| 20 DMA Support | 1 day ago |
| Down 2 % | 1 day ago |
| Possible NR7 | 1 day ago |
| 60 Minute Opening Range Breakdown | 2 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. It also focuses on using its intracellular platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is headquartered in Bala Cynwyd, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Rare Diseases Drug Discovery Genetic Diseases Progressive Clinical Pharmacology Fusion Protein Ataxia Friedreich's Ataxia Trinucleotide Repeat Disorders
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Rare Diseases Drug Discovery Genetic Diseases Progressive Clinical Pharmacology Fusion Protein Ataxia Friedreich's Ataxia Trinucleotide Repeat Disorders
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.68 |
| 52 Week Low | 2.18 |
| Average Volume | 432,284 |
| 200-Day Moving Average | 5.52 |
| 50-Day Moving Average | 7.57 |
| 20-Day Moving Average | 7.27 |
| 10-Day Moving Average | 7.72 |
| Average True Range | 0.52 |
| RSI (14) | 48.72 |
| ADX | 16.07 |
| +DI | 22.49 |
| -DI | 24.60 |
| Chandelier Exit (Long, 3 ATRs) | 6.76 |
| Chandelier Exit (Short, 3 ATRs) | 7.48 |
| Upper Bollinger Bands | 8.53 |
| Lower Bollinger Band | 6.02 |
| Percent B (%b) | 0.54 |
| BandWidth | 34.42 |
| MACD Line | 0.05 |
| MACD Signal Line | 0.01 |
| MACD Histogram | 0.0428 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.76 | ||||
| Resistance 3 (R3) | 7.75 | 7.61 | 7.69 | ||
| Resistance 2 (R2) | 7.61 | 7.52 | 7.62 | 7.67 | |
| Resistance 1 (R1) | 7.50 | 7.46 | 7.43 | 7.51 | 7.65 |
| Pivot Point | 7.36 | 7.36 | 7.33 | 7.37 | 7.36 |
| Support 1 (S1) | 7.25 | 7.27 | 7.18 | 7.26 | 7.11 |
| Support 2 (S2) | 7.11 | 7.21 | 7.12 | 7.09 | |
| Support 3 (S3) | 7.00 | 7.11 | 7.07 | ||
| Support 4 (S4) | 7.01 |
